본문으로 건너뛰기
cccskills
무료GitHub에 공개

es-cgm-vs-smbg-t1d-mdi

Recommends CGM over SMBG for type 1 diabetes patients on multiple daily injections to reduce hypoglycemia risk. Triggered by clinician questions such as "Should I use CGM or SMBG for this T1D patient on MDI?" or "Is CGM preferred for glucose monitoring in this patient?"

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL
설치 방법 보기

포함된 파일(1)

  • SKILL.md2.6 KB

SKILL.md(원문)

설치하기 전에 에이전트에게 전달되는 지시 내용을 확인할 수 있습니다.

CGM vs SMBG for Type 1 Diabetes on MDI

STEP 1 — Gather Information

Confirm type 1 diabetes diagnosis and current multiple daily injection (MDI) regimen; assess hypoglycemia history (frequency, severity, nocturnal events), hypoglycemia awareness, patient’s ability/willingness to use CGM (dexterity, visual/hearing for alerts), insurance coverage/access, and need for structured education on device use and data interpretation.

STEP 2 — Rule In / Rule Out

Rule out CGM if the patient cannot safely operate the device (e.g., severe dexterity impairment, uncontrolled dermatitis, lack of training resources, or explicit refusal); otherwise rule in for CGM consideration.

STEP 3 — Classify or Stratify

Stratify by hypoglycemia risk: high (history of severe hypoglycemia requiring assistance, hypoglycemia unawareness, frequent nocturnal events) versus moderate (no severe events but suboptimal glycemic control); prioritize CGM for high‑risk patients.

STEP 4 — Decide

Recommend initiating real‑time CGM (or intermittently scanned CGM with predictive alerts) rather than SMBG alone; provide structured education on device use, troubleshooting, and data interpretation; retain access to SMBG for calibration/validation and sensor warm‑up periods.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on CGM values for insulin dosing without confirmatory SMBG during sensor warm‑up, when symptoms mismatch sensor readings, or if sensor malfunctions; do not omit structured education; do not use CGM in patients with substances that interfere with sensor accuracy (e.g., high‑dose vitamin C, hydroxyurea) without verification; do not assume CGM eliminates the need for SMBG entirely.

Concrete Clinical Example

A 22‑year‑old college student with T1D on MDI (glargine basal, lispro bolus) reports two nocturnal hypoglycemia episodes requiring assistance in the past month and fears hypoglycemia disrupting sleep; after confirming MDI regimen and hypoglycemia risk, CGM is initiated with education, and SMBG is retained for calibration and symptom‑sensor mismatches.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

리뷰

아직 리뷰가 없습니다. 사용해 본 소감을 남겨 주세요.

댓글

로그인 없이 쓸 수 있습니다. 사용 후기, 질문, 작동하지 않은 환경 등을 편하게 남겨 주세요.

아직 댓글이 없습니다. 첫 댓글을 남겨 보세요.

보내면 바로 공개됩니다. 이메일 주소나 전화번호 같은 개인 정보는 쓰지 마세요. URL은 2개까지입니다.

0 / 1,000자

이 양식은 reCAPTCHA로 보호되며 Google 개인정보처리방침 및 서비스 약관이 적용됩니다.

같은 저장소의 스킬

780g-pump-adjustment

무료

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-acth-stim-test-interpretation

무료

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-adrenal-crisis-treatment

무료

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-aed-ai-education

무료

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-aed-lt4-monitoring

무료

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

ata-cortisol-cutoff-ai-diagnosis

무료

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.

dromlakhani/MD2SKILL142026년 10월 20일 업데이트

dromlakhani의 스킬 모두 보기

이 스킬의 문제 신고